These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37658561)

  • 21. Hybrid simultaneous whole-body 2-[
    Jamet B; Carlier T; Bailly C; Bodet-Milin C; Monnet A; Frampas E; Touzeau C; Moreau P; Kraeber-Bodere F
    Eur Radiol; 2023 Sep; 33(9):6438-6447. PubMed ID: 37022439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretreatment
    Abe Y; Narita K; Kobayashi H; Kitadate A; Miura D; Takeuchi M; O'uchi E; O'uchi T; Matsue K
    Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1325-1333. PubMed ID: 30687892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
    Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
    Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging CXCR4 receptors expression for staging multiple myeloma by using
    Shekhawat AS; Singh B; Malhotra P; Watts A; Basher R; Kaur H; Hooda M; Radotra BD
    Br J Radiol; 2022 Aug; 95(1136):20211272. PubMed ID: 35731811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple myeloma.
    Peller PJ
    PET Clin; 2015 Apr; 10(2):227-41. PubMed ID: 25829088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma.
    Mosci C; Pericole FV; Oliveira GB; Delamain MT; Takahashi MES; Carvalheira JBC; Etchebehere ECSC; Santos AO; Miranda ECM; Lima MCL; Amorim BJ; de Souza CA; Lorand-Metze I; Ramos CD
    Nucl Med Commun; 2020 Oct; 41(10):1081-1088. PubMed ID: 32732603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marrow uptake on FDG PET/CT is associated with progression from smoldering to symptomatic multiple myeloma.
    Amini B; Nakache YN; Nardo L; Manasanch EE; Sun J; Lenchik L; Boutin RD
    Skeletal Radiol; 2021 Jan; 50(1):79-85. PubMed ID: 32621061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders.
    Ulaner GA; Landgren CO
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101148. PubMed ID: 32139013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic performance of
    Basha MAA; Hamed MAG; Refaat R; AlAzzazy MZ; Bessar MA; Mohamed EM; Ahmed AF; Tantawy HF; Altaher KM; Obaya AA; Afifi AHM
    Jpn J Radiol; 2018 Jun; 36(6):382-393. PubMed ID: 29671193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS.
    Giovanella L; Taborelli M; Ceriani L; Zucca E; Cavalli F; Delaloye AB
    Nucl Med Commun; 2008 Jun; 29(6):535-41. PubMed ID: 18458600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of thymidine kinase serum levels by novel method DiviTum in multiple myeloma and monoclonal gammopathy of undetermined significance - comparison with imaging methods 99mTc-MIBI scintigraphy and 18F-FDG PET/CT.
    Bacovsky J; Myslivecek M; Minarik J; Scudla V; Pika T; Zapletalova J; Petrova P; Bartkova M; Adam T; Gronowitz SJ
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Mar; 159(1):135-8. PubMed ID: 24572488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.
    Sachpekidis C; Goldschmidt H; Dimitrakopoulou-Strauss A
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31905752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Skeletal changes in plasma cell dyscrasias].
    Weber TF; Mokry T
    Radiologe; 2021 Dec; 61(12):1078-1089. PubMed ID: 34889973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma.
    Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
    Acta Radiol; 2008 May; 49(4):427-35. PubMed ID: 18415787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma.
    Messiou C; Porta N; Sharma B; Levine D; Koh DM; Boyd K; Pawlyn C; Riddell A; Downey K; Croft J; Morgan V; Stern S; Cheung B; Kyriakou C; Kaczmarek P; Winfield J; Blackledge M; Oyen WJG; Kaiser MF
    Radiol Imaging Cancer; 2021 Sep; 3(5):e210048. PubMed ID: 34559006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients.
    Bailly C; Leforestier R; Jamet B; Carlier T; Bourgeois M; Guérard F; Touzeau C; Moreau P; Chérel M; Kraeber-Bodéré F; Bodet-Milin C
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28218709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma.
    Jamet B; Bailly C; Carlier T; Touzeau C; Michaud AV; Bourgeois M; Moreau P; Bodet-Milin C; Kraeber-Bodere F
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32092901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of [
    Stolzenburg A; Lückerath K; Samnick S; Speer M; Kneer K; Schmid JS; Grigoleit GU; Hofmann S; Beer AJ; Bunjes D; Knop S; Buck AK; Einsele H; Lapa C
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1694-1704. PubMed ID: 29610955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?
    Spira D; Weisel K; Brodoefel H; Schulze M; Kaufmann S; Horger M
    Acad Radiol; 2012 Jan; 19(1):89-94. PubMed ID: 22142681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.